SOLICITATION NOTICE
Q -- Mutation Analysis of Alagille Syndrome Associated Genes, JAG1 and NOTCH2
- Notice Date
- 8/17/2010
- Notice Type
- Presolicitation
- NAICS
- 541380
— Testing Laboratories
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Blvd., EPS Suite 600, Rockville, Maryland, 20852
- ZIP Code
- 20852
- Solicitation Number
- NCI-100189-TG
- Archive Date
- 9/15/2010
- Point of Contact
- Terry Galloway, Phone: 301-402-4509, Caren N Rasmussen, Phone: (301) 402-4509
- E-Mail Address
-
gallowaytl@mail.nih.gov, cr214i@nih.gov
(gallowaytl@mail.nih.gov, cr214i@nih.gov)
- Small Business Set-Aside
- N/A
- Description
- Contracting Office Address Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Blvd. EPS Suite 600, Rockville, MD, 20852, UNITED STATES Description The National Cancer Institute (NCI), Division of Cancer Epidemiology and Genetics (DCEG) plans to procure on a sole source basis the Mutation Analysis of Alagille Syndrome Associated Genes, JAG1 and NOTCH2, in Nephroblastoma and Hepatocellular Carcinoma from The Children's Hospital of Philadelphia, 1007A ARC, 3615 Civic Center Boulevard, Philadelphia, PA 19104. The supplies and services herein are being procured in accordance with the simplified acquisition procedures as authorized by FAR Part 13.106 (b)(1). The North American Industry Classification System code is 541380 and the business size standard is $12 Million. Only one award will be made as a result of this solicitation. This will be awarded as a firm fixed price type contract. Period of Performance shall be for twelve (12) months from date of award. Alagille syndrome (AGS, OMIM 118450) is an autosomal multisystem disorder involving the liver, heart, eyes, face, and skeleton. Patients also have characteristic facial appearance. The clinical features may be highly variable; however, the patients often have cholestasis, congenital heart defects, posterior embryotoxon in the eye, and butterfly vertebrae. Renal and central nervous abnormalities may also occur. The disorder is caused by germline mutations of JAG1 in most patients. In addition, a subset of AGS cases is caused by germline mutations of NOTCH2. Notably, both JAG1 and NOTCH2 are crucial components of the Notch signaling pathway, which controls numerous cell-fate specification events. Indeed, dysregulated Notch signaling has been documented in several malignancies. Although AGS is not considered a cancer predisposition syndrome, several case reports describe AGS patients who also have either hepatocellular carcinoma (HCC) or nephroblastoma. The contractor shall test the hypothesis that somatic mutations of JAG1 and NOTCH2 contribute to sporadic cases of HCC and nephroblastoma. The contractor shall test whether rare cases of HCC or nephroblastoma may be associated with germline mutations of JAG1 or NOTCH2 in patients with previously-unrecognized AGS. The Children's Hospital of Philadelphia and the laboratory of Dr. Nancy Spinner is uniquely qualified to carry out the laboratory analysis. The Children's Hospital of Philadelphia and Dr. Spinner is the internationally recognized Alagille syndrome expert, and was first to describe both genes (JAG1 and NOTCH2) as disease causative genes. As the Director of CytoGenomics at The Children's Hospital of Philadelphia, she has immeasurable experience in the analysis of these genes, and has published her findings in many scientific journals. There is no other known source available with the expertise to conduct the mutation analysis of these genes in nephroblastoma and hepatocellular carcinoma. This notice is not a request for competitive quotation. However, if any interested party believes it can meet the above requirement, it may submit a statement of capabilities. The statement of capabilities and any other information furnished must be in writing and must contain material in sufficient detail to allow NCI to determine if the party can perform the requirement. Capability statements must be received in the contracting office by 11:00 AM EST, on August 31, 2010. For further information, please contact Terry Galloway, Contract Specialist via electronic mail at gallowaytl@mail.nih.gov. A determination by the Government not to compete this proposed requirement based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. No collect calls will be accepted. No faxed or emailed capability statements will be accepted. In order to receive an award, contractors must be registered and have valid certification in the Central Contractor Registration (CCR) and the Online Representations and Certifications Applications (ORCA). Reference: NCI-100189-TG on all correspondence.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/RCB/NCI-100189-TG/listing.html)
- Record
- SN02244359-W 20100819/100818000359-540ac9b15e4dd390d74be6aa6c2dd17d (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |